Pablo Mando
@PabloMando
Clinical Oncologist, Breast and Gyn Unit, CEMIC, Buenos Aires, Argentina. YOC member @myESMO @SUMAargentina Board member
Más información: aaoc.org.ar/comitemolecula…
At #ESMOGI25 ? Come and join us at 12:45 for the Young Oncologists Mentorship session! 🌟We got 3 amazing and inspiring speakers selected specially for you 🌟
POST CHICAGO 2025 Simposio de la Industria Cáncer de Endometrio: Un enfoque multidisciplinario para un mejor abordaje Coordina: Dr. Pablo Mandó Disertantes: Dr. Pablo Mandó, Dr. Federico Bianchi, Dra. Mariana Eiben, Dr. Andrés Rodríguez Mignola Patrocina Laboratorio GSK
Sala completa en Post Chicago de la @aaoncoclinica Momento importante de la oncologia argentina todos los años!!! Felicitaciones a los organizadores @Martin_AngelMD
Más información: aaoc.org.ar/comitemolecula…
BRCA BCY global study with 1 ,865 BRCA mutations carriers with HR+ BC where @SUMAargentina participated actively provides evidence that OFS combined with ET improved DFS and OS @paolazagam @matteolambe #ASCO25
T-DXd + P demonstrated a statistically significant and clinically meaningful PFS benefit vs THP (mPFS 40.7m vs 26.9m). @stolaney1 Still many question to be adressed highlighted in the excelent discussion by Dr. Isaacs #ASCO25
Wouldn't it have been more enlightening if the SERENA6 design had been like this? Amazing discussion by @AngieDemichele at #ASCO25 Plenary Session
TRADE study: initial dose escalation strategy for adjuvant abemaciclib allowed a greater number of patients (70.8%) to reach and maintain 150 mg BID dosing at 12-weeks than observed in monarchE 60% and 93.3% were continuing therapy at 12 weeks @elmayermd #ASCO25
Adjuvant Ribociclib benefit irrespective of menopausal status. Low rate of discontinuation in younger patients @KalinskyKevin #ASCO25
Looking forward to the rapid oral early #BreastCancer session in Hall B1 this morning…a real honor to be here #ASCO25 !!! @OncoAlert @ASCO @KalinskyKevin @UniGenova @SanMartino_Ge
In DB06 biomarker-evaluable population, there was a potentially greater efficacy benefit with T-DXd in the BRCA1/2 mutation subgroup (albeit with a small sample size). Biological rationale??? #ASCO2025 @RebeccaDSing
Oral paclitaxel is here. Now lets work to give access to our patients to another oral chemotherapy option! #ASCO2025
Inavolisib addition to Palbociclib + Fulvestrant improved OS (34m vs 27m), PFS (17m vs 7m), ORR (62% vs 28%) and DOR (19m vs 11m) in a poor risk population. Impressive delay to first subsequent CT of almost 2y!!! #ASCO2025
Vepdegestrant (oral PROTAC) demonstrated significant improvement in PFS in patients with ESR 1m ER+/HER2- mBC and a favorable safety profile. A new kid in the block after CDKi PD. A question is if Fulvestrant monotherapy is the proper control arm #ASCO2025 @ErikaHamilton9
As always @ines_vazluis gives a profound lecture on the potential of eHealth solutions for therapy management and follow up care. Highlighting the need for: ▪️Coordinated care ▪️Patient empowerment ▪️Robust digital infrastructure #ASCO2025
Interesting data of co-inhibition of Her2 and PIK3CA in heavly pretreated patients #ASCO2025
Promising activity of Sac-TMT as 1L treatment for patients with mTNBC: ⚪️ORR 70.7% ⚪️mDoR 12.2 mo ⚪️mPFS 13.4 mo ⚪️ 12-mo PFS rate 64.6%. #ASCO2025
AI improved pathogists’ concordance in HER2 determination #ASCO2025
#ASCO25 abstracts are out! INAVO120: HR+ MBC, PIK3CA-mut Inavolisib + palbo + fulv vs placebo combo: - OS: 34 vs 27 m (HR 0.67, 95% CI 0.50–0.91) - PFS: 17.2 vs 7.3 m - ORR: 62.7% vs 28% - Time to chemo: 35.6 vs 12.6 m ⚠️ Hyperglycemia (any grade): 63.4% vs 13.5% @OncoAlert